Emactuzumab
- CAS No.
- 1448221-67-7
- Chemical Name:
- Emactuzumab
- Synonyms
- Emactuzumab;RO 5509554|||RG 7155;Emactuzumab (anti-CSF1R);Research Grade Emactuzumab;Research Grade Emactuzumab(DHC25202)
- CBNumber:
- CB98080911
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 6FY6EI1X8R |
| NCI Drug Dictionary | emactuzumab |
Emactuzumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0612557 | Emactuzumab 97.60% | 1448221-67-7 | 1mg | $379 | 2026-06-04 | Buy |
| ChemScene | CS-0612557 | Emactuzumab 97.60% | 1448221-67-7 | 5mg | $975 | 2026-06-04 | Buy |
| ChemScene | CS-0612557 | Emactuzumab 97.60% | 1448221-67-7 | 10mg | $1517 | 2026-06-04 | Buy |
| Biorbyt Ltd | orb1290207 | Emactuzumab >95% | 100μg | $280 | 2026-05-06 | Buy | |
| Biorbyt Ltd | orb1290207 | Emactuzumab >95% | 1mg | $820 | 2026-05-06 | Buy |
Emactuzumab Chemical Properties, Uses, Production
Uses
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) [1][2].
in vivo
Emactuzumab(RG 7155) (i.v.; 0.1, 1, 10, 30 and 100 mg/kg; once) increases CSF-1 concentration in nonhuman primates’ peripheral blood[2].
RG7155 (i.v.; 0, 30, and 100 mg/kg; once weekly; for 2 weeks) depletes CSF-1R+CD163+ macrophages in vivo[2].
| Animal Model: | cynomolgus monkeys Macaca fascicularis[2] |
| Dosage: | 0.1, 1, 10, 30 and 100 mg/kg (male cynomolgus monkeys) 0, 30, and 100 mg/kg (male and female cynomolgus) |
| Administration: | i.v., once (male cynomolgus monkeys) i.v., once weekly, for 2 weeks(male and female cynomolgus) |
| Result: | Increased CSF-1 concentration in serum. Efficiently reduced CSF-1R and CD68+163+ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys. |
References
[1] Philippe A Cassier, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015 Aug;16(8):949-56. DOI:10.1016/S1470-2045(15)00132-1
[2] Carola H Ries, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59. DOI:10.1016/j.ccr.2014.05.016
Emactuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Emactuzumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
View Latest Price from Emactuzumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Emactuzumab
1448221-67-7
|
$289.00-1160.00 | 97.3% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Emactuzumab
1448221-67-7
- $289.00-1160.00
- 97.3% (SEC-HPLC)
- TargetMol Chemicals Inc.
